-
公开(公告)号：US11116826B2
公开(公告)日：2021-09-14
申请号：US17229556
申请日：2021-04-13
发明人： Toni Weinschenk , Jens Fritsche , Harpreet Singh , Andrea Mahr , Martina Ott , Claudia Wagner , Oliver Schoor
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10898561B2
公开(公告)日：2021-01-26
申请号：US17018695
申请日：2020-09-11
发明人： Toni Weinschenk , Jens Fritsche , Harpreet Singh , Andrea Mahr , Martina Ott , Claudia Wagner , Oliver Schoor
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10898560B2
公开(公告)日：2021-01-26
申请号：US17018572
申请日：2020-09-11
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Claudia Wagner , Julia Leibold , Colette Song
IPC分类号： A61K39/00 , C07K16/28 , G16B20/20 , C07K14/74 , C07K14/725 , C07K14/47 , A61P35/00 , A61K35/17 , G01N33/574 , C12Q1/6886 , C12N5/0783 , C07K16/30
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10898559B2
公开(公告)日：2021-01-26
申请号：US16915707
申请日：2020-06-29
发明人： Andrea Mahr , Toni Weinschenk , Oliver Schoor , Jens Fritsche , Harpreet Singh , Claudia Wagner , Julia Leibold , Colette Song
IPC分类号： A61K39/00 , G16B20/20 , A61K35/17 , C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12Q1/6886 , G01N33/574 , A61P35/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US10357551B2
公开(公告)日：2019-07-23
申请号：US15869471
申请日：2018-01-12
发明人： Toni Weinschenk , Jens Fritsche , Harpreet Singh , Andrea Mahr , Martina Ott , Claudia Wagner , Oliver Schoor
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20180306789A1
公开(公告)日：2018-10-25
申请号：US16025434
申请日：2018-07-02
发明人： Leonie Alten , Sebastian Bunk , Dominik Maurer , Claudia Wagner
IPC分类号： G01N33/574 , C07K16/30 , C07K14/725 , C07K16/28 , A61K39/395 , A61K35/17 , A61P35/00 , C07K14/705 , A61K39/00 , G01N33/58
摘要： The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US11932689B2
公开(公告)日：2024-03-19
申请号：US17125135
申请日：2020-12-17
发明人： Felix Unverdorben , Sebastian Bunk , Martin Hofmann , Dominik Maurer , Meike Hutt , Claudia Wagner , Leonie Alten
IPC分类号： C07K14/725 , A61P35/00 , C07K14/775 , C07K14/78 , C07K16/18 , C07K16/28 , C12N5/0783 , C12N15/62
CPC分类号： C07K16/28 , A61P35/00 , C07K14/7051 , C07K14/775 , C07K14/78 , C07K16/18 , C07K16/2809 , C12N5/0636 , C12N15/62 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03 , C07K2319/33 , C12N2510/00
摘要： The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
公开(公告)号：US11859009B2
公开(公告)日：2024-01-02
申请号：US17934303
申请日：2022-09-22
发明人： Gabriele Pszolla , Martin Hofmann , Meike Hutt , Sebastian Bunk , Felix Unverdorben , Frank Schwoebel , Dominik Maurer , Maike Jaworski , Claudia Wagner , Florian Schwoerer , Heiko Schuster
CPC分类号： C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要： The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US11111294B2
公开(公告)日：2021-09-07
申请号：US16733845
申请日：2020-01-03
发明人： Claudia Wagner , Leonie Alten , Sebastian Bunk , Dominik Maurer
IPC分类号： C07K14/725 , C07K16/26 , C07K14/81 , C07K16/28 , C07K16/38 , C12N5/0783 , C12N15/85
摘要： The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular the TAA Serine protease inhibitor Kazal-type 2 (SPINK2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and SPINK2 binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of SPINK2 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
10.发明授权公开(公告)号：US10561718B2
公开(公告)日：2020-02-18
申请号：US16563096
申请日：2019-09-06
发明人： Toni Weinschenk , Jens Fritsche , Harpreet Singh , Andrea Mahr , Martina Ott , Claudia Wagner , Oliver Schoor
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.024 秒)
